source
- Regeneron halts Phase 1/2 uveitis antibody trial over unfavorable risk-benefit profileRegeneron has stopped a Phase 1/2 study of its anti‑inflammatory antibody REGN7041 in non‑infectious uveitis, citing an unfavorable benefit‑risk assessment. The antibody targets CD3 on immune cell…
- Amylyx to seek FDA approval for avexitide after Phase 3 success in post-bariatric hypoglycemiaAmylyx announced plans to file a new drug application for avexitide, a GLP-1 receptor antagonist, after a Phase 3 trial showed reduction in serious hypoglycemia in patients who had gastric bypass s…